Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Braveheart Bio, Inc.BRVE · Entity 4564 | Chief Development Officer | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Braveheart Bio, Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 332,161 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 1,111 · Balance 332,161 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-08-04 | Direct | 300,000 |
Reported balance
After 2026-08-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-05 · Grant · Acquired 300,000 · Balance 300,000 F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 7, 2026 20:30 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | PurchaseCommon Stock | 1,111 | $18.00 | $19,998.00 |
DisclosureSEC source: 0001470831-26-000799 · wk-form4_1786134657.xml · nonDerivative · entry 1 Anderson Michele A. · CIK 0002141644 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,161 Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:30 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000799 · wk-form4_1786134657.xml · derivative · entry 2 Anderson Michele A. · CIK 0002141644 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-08-04 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.